Published in J Clin Oncol on December 01, 1993
Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group. Clin Cancer Res (2010) 1.07
Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Br J Cancer (1996) 1.06
Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors. J Nucl Med (2010) 0.88
Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study. Br J Cancer (2001) 0.86
Preclinical profile of cabazitaxel. Drug Des Devel Ther (2014) 0.85
Efficacy of cabazitaxel in mouse models of pediatric brain tumors. Neuro Oncol (2014) 0.84
Pharmacokinetic evaluation of Paclitaxel in South Indian cancer patients: a prospective study. J Young Pharm (2011) 0.81
Treatment of neuroblastoma and rhabdomyosarcoma using RGD-modified liposomal formulations of patupilone (EPO906). Int J Nanomedicine (2013) 0.75
Phase I and Phase II Objective Response Rates are Correlated in Pediatric Cancer Trials: An Argument for Better Clinical Trial Efficiency. J Pediatr Hematol Oncol (2016) 0.75
Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376). Pediatr Blood Cancer (2009) 0.75
Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 8.25
The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol (1995) 5.36
Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med (1997) 4.13
Nomenclature for N-acetyltransferases. Pharmacogenetics (1995) 3.59
The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med (1986) 3.27
Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med (1998) 2.59
Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. J Clin Oncol (1990) 2.48
Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther (2012) 2.48
Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. J Clin Oncol (2000) 2.40
The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther (2013) 2.40
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med (1997) 2.38
Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study. Am J Surg Pathol (1998) 2.32
Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia (2009) 2.24
Red cells from glutathione peroxidase-1-deficient mice have nearly normal defenses against exogenous peroxides. Blood (2000) 2.19
Myeloid neoplasia in children treated for solid tumours. Lancet (1990) 2.18
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther (2012) 2.12
Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol (1990) 2.11
Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia (2000) 1.94
Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas. J Clin Oncol (1996) 1.90
Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood (2000) 1.89
Alveolar soft part sarcoma in children and adolescents: clinical features and outcome of 11 patients. Med Pediatr Oncol (1996) 1.85
Delay in the diagnosis of pediatric brain tumors. Am J Dis Child (1986) 1.83
Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol (2001) 1.82
Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther (2008) 1.82
Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease. J Clin Oncol (1995) 1.73
Interval between symptom onset and diagnosis of pediatric solid tumors. J Pediatr (1991) 1.71
The spectrum of Evans' syndrome. Arch Dis Child (1997) 1.69
P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci U S A (1996) 1.65
Concordance of DMET plus genotyping results with those of orthogonal genotyping methods. Clin Pharmacol Ther (2012) 1.62
Tumor size as a predictor of outcome in pediatric non-metastatic osteosarcoma of the extremity. Pediatr Blood Cancer (2004) 1.61
Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood (1998) 1.60
Hepatocellular carcinoma in children associated with Gardner syndrome or familial adenomatous polyposis. J Pediatr Hematol Oncol (1998) 1.59
Topoisomerase II inhibitor-related acute myeloid leukaemia. Br J Haematol (2000) 1.57
Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol (2004) 1.57
Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission. Cancer (1970) 1.56
Relationship between cytotoxicity and site-specific DNA recombination after in vitro exposure of leukemia cells to etoposide. J Natl Cancer Inst (1996) 1.54
Recurrent childhood lymphocytic leukemia following cessation of therapy: treatment and response. Cancer (1976) 1.53
Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital. J Clin Oncol (1998) 1.52
Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol (2001) 1.52
Two new acute lymphoblastic leukemia cell lines with early B-cell phenotypes. Blood (1982) 1.52
Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics (1996) 1.50
Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest (1996) 1.49
Levels of p53 protein increase with maturation in human hematopoietic cells. Cancer Res (1991) 1.49
Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia (2000) 1.48
Prognostic features of Ewing sarcoma on plain radiograph and computed tomography scan after initial treatment. A Pediatric Oncology Group study (8346) Cancer (1993) 1.44
Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol (2000) 1.44
Major histocompatibility complex-restricted lysis of neuroblastoma cells by autologous cytotoxic T lymphocytes. J Immunother (2001) 1.43
Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia (2006) 1.42
Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol (1999) 1.41
Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet (1999) 1.40
The role of photodynamic therapy in posterior fossa brain tumors. A preclinical study in a canine glioma model. J Neurosurg (1993) 1.40
Coding sequences of the tal-1 gene are disrupted by chromosome translocation in human T cell leukemia. J Exp Med (1990) 1.39
Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks. Pharmacogenetics (1996) 1.38
Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma. J Clin Oncol (2001) 1.38
Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol (2000) 1.37
Bone sarcomas of the head and neck in children: the St Jude Children's Research Hospital experience. Cancer (2000) 1.37
The t(1;14)(p34;q11) is nonrandom and restricted to T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood (1990) 1.36
A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci U S A (1995) 1.36
Colon carcinoma in children and adolescents. A review of 30 cases. Cancer (1985) 1.36
Second malignant neoplasms in children treated for rhabdomyosarcoma. Intergroup Rhabdomyosarcoma Study Committee. J Clin Oncol (1993) 1.35
ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence. Leukemia (2010) 1.34
Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet (1994) 1.32
Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing's sarcoma studies. Cancer (1990) 1.30
Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol (1994) 1.29
Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest (1994) 1.29
Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood (1994) 1.29
Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood (1995) 1.29
Coordinated treatment of childhood rhabdomyosarcoma with surgery, radiotherapy, and combination chemotherapy. Cancer Res (1972) 1.25
Bone marrow metastases at diagnosis in children and adolescents with rhabdomyosarcoma. A report from the intergroup rhabdomyosarcoma study. Cancer (1984) 1.25
Hemoglobin autoxidation and regulation of endogenous H2O2 levels in erythrocytes. Free Radic Biol Med (2005) 1.23
Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther (1995) 1.23
Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. Mol Pharmacol (1997) 1.23
Metastases detected at the time of diagnosis of primary pediatric extremity osteosarcoma at diagnosis: imaging features. Cancer (1999) 1.22
Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group study. Blood (1990) 1.20
"Large cell/anaplastic" medulloblastomas: a Pediatric Oncology Group Study. J Neuropathol Exp Neurol (2000) 1.19
Phagocytosis of neutrophils by marrow macrophages in childhood chronic benign neutropenia. J Pediatr (1981) 1.19
Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. Blood (1997) 1.18
Response of childhood rhabdomyosarcoma to combination chemotherapy. J Pediatr (1969) 1.18
A new familial cancer syndrome? A spectrum of malignant and benign tumors including retinoblastoma, carcinoma of the bladder and other genitourinary tumors, thyroid adenoma, and a probable case of multifocal osteosarcoma. J Natl Cancer Inst (1977) 1.18
Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia (2003) 1.18
Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia (1997) 1.18
Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicin. Leukemia (1997) 1.18
Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol (1996) 1.18
Cisplatin in recurrent pediatric brain tumors. A POG Phase II study. A Pediatric Oncology Group Study. Cancer (1985) 1.17
Breast metastases in children with rhabdomyosarcoma. Cancer (1980) 1.17
Sarcomas (other than Ewing's) of flat bones in children and adolescents. A clinicopathologic study. Cancer (1990) 1.15
Metastatic epidural tumors in children. Med Pediatr Oncol (1982) 1.15
Clinical investigations in the treatment of meningeal leukemia: radiation therapy regimens vs. conventional intrathecal methotrexate. Blood (1969) 1.15
Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res (2001) 1.15